# OnCo record idea-lung-resistance-directed-sequencing-at-every-progression (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-lung-resistance-directed-sequencing-at-every-progression" ;
  schema:name "Make resistance a diagnosis: sequence at every progression and choose the next line from what the tumour became"@en ;
  schema:description "When a targeted drug stops working, the tumour has usually changed in a way you can read. Most patients still move to the next treatment on a protocol rather than on a test of what actually happened."@en ;
  schema:url <https://onco.cc/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "lung-evidence" ;
  onco:related <https://onco.cc/roadmaps/ctdna-tests/>, <https://onco.cc/roadmaps/diagnostics-roadmap/>, <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/ctdna/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-care-fragmentation/>, <https://onco.cc/bottlenecks/b-data-silos/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/>, <https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/>, <https://onco.cc/key-papers/paper-cho-mariposa-amivantamab-lazertinib-nejm-2024/>, <https://onco.cc/key-papers/paper-jamal-hanjani-tracerx-evolution-nsclc-nejm-2017/> .